The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-06831-2
Abstract: To evaluate the sterility, stability, and efficacy of repackaged ziv-aflibercept in 1-mL plastic tuberculin syringes for intravitreal injection after storage for up to 90 days at controlled (4 °C) and ambient (25.8 °C) temperature. A… read more here.
Keywords: stability efficacy; repackaged ziv; ziv; ziv aflibercept ... See more keywords
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003569
Abstract: Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced… read more here.
Keywords: aflibercept plus; ziv; ziv aflibercept; plus pembrolizumab ... See more keywords
Intravitreal Ziv‐Aflibercept: Clinical Effects and Economic Impact
Sign Up to like & getrecommendations! Published in 2017 at "Asia-Pacific Journal of Ophthalmology"
DOI: 10.22608/apo.2017263
Abstract: Abstract: During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard‐of‐care treatment for a variety of chorioretinal vascular conditions. The off‐label, intravitreal use of ziv‐aflibercept (Zaltrap) has… read more here.
Keywords: intravitreal ziv; ziv aflibercept; clinical effects; ziv ... See more keywords